Cure8 research brief
This study could clarify which imaging test—MRE or IUS—is more accurate or appropriate for monitoring treatment response in Crohn's disease, potentially standardising follow-up and informing patient and clinician choices.
Adults with Crohn's disease, clinicians ordering follow-up imaging (gastroenterologists, radiologists), and researchers in imaging and IBD monitoring.
This is a published study protocol (MANTRA, NCT06800326) recruiting adults (≥16) with luminal Crohn's disease starting or on steroids, immunomodulators, biologics/biosimilars, or small molecules.
Participants will have both MRE and IUS performed within 6 weeks of each other during follow-up; one scan will be routine care and the other performed as part of the study. Radiologists interpreting each test will be masked to the other modality, and a multidisciplinary consensus panel using all clinical information will serve as the reference standard.
The study will measure comparative accuracy for established response categories, explore the effect of which modality was used at baseline, evaluate scoring systems, assess management impact, and collect patient-reported imaging preferences. Results are planned for peer-reviewed publication and conference presentation.
This is a published protocol/abstract (BMJ Open) describing planned methods; it does not present study results. The trial is multicentre in the UK and Belgium with a planned sample of ~155 patients (registered NCT06800326).
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: SAT is a consultant to AstraZeneca, has research grant support from Takeda and is a shareholder in Motilent. The other authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early intestinal ultrasound may predict one-year endoscopic remission in Crohn's disease, offering a noninvasive tool to guide treatment decisions and possibly reduce the need for some colonoscopies.
This study suggests intestinal ultrasound findings early after diagnosis — especially achieving “transmural remission” within 3 months — may predict better 1-year outcomes (sustained steroid-free remission and less need...
This study suggests using both faecal calprotectin and intestinal ultrasound together can better identify patients who reach deeper, transmural healing — and those patients had lower risk of bowel-damage progression....
